Treatment.com AI Partners with Aiyibotong to Expand Clinical Decision Support in China

Treatment.com International ( (TSE:TRUE) ) has shared an update.

Treatment.com AI Inc. has signed a Collaborative Agreement with Beijing Aiyi Botong Information Technology Ltd to explore commercial opportunities for Clinical Decision Support Systems (CDSS) in China and the Far East. The partnership aims to combine Aiyibotong’s CDSS with Treatment’s Global Library of Medicine to enhance patient support and increase market share. This collaboration aligns with the growing investment in digital health in China, expected to reach $45 billion in 2025, and the CDSS market projected to double by 2030. The agreement includes co-marketing efforts and the development of an AI-based CDSS for the global market, leveraging both companies’ technologies and expertise.

More about Treatment.com International

Treatment.com AI Inc. is a company focused on providing enhanced clinical decision support for healthcare professionals and patients using innovative technologies such as artificial intelligence and machine learning. It collaborates with Aiyibotong, a China-based healthcare information technology company that offers clinical decision support solutions for medical professionals in hospitals and clinics.

YTD Price Performance: -6.06%

Average Trading Volume: 10,013

Technical Sentiment Signal: Buy

Current Market Cap: $15.15M

For a thorough assessment of TRUE stock, go to TipRanks’ Stock Analysis page.